this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

Chemical Component Summary

FormulaC14 H14 Cl N S
Molecular Weight263.79 g/mol
Isomeric SMILESClc1ccccc1CN1CCc2sccc2C1

Chemical Details

Formal Charge0
Atom Count31
Chiral Atom Count0
Chiral Atomsn/a
Bond Count33
Aromatic Bond Count11
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00208 Stereoisomeric match
DescriptionTiclopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
  • Ticlopidina
  • Ticlopidinum
SaltsTiclopidine Hydrochloride
Brand Names
  • Alti-ticlopidine - Tab 250mg
  • Apo-ticlopidine Tablets
  • Dom-ticlopidine
  • Mylan-ticlopidine
  • Nu-ticlopidine 250 mg
Affected OrganismHumans and other mammals
IndicationUsed in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
PharmacologyTiclopidine is a prodrug that is metabolised to an as yet undetermined metabolite that acts as a platelet aggregation inhibitor. Inhibition of platelet aggregation causes a prolongation of bleeding time. In its prodrug form, ticlopidine has no significant in vitro activity at the concentrations attained in vivo.
Mechanism of actionThe active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of ticlopidine.
Route of administrationOral
  • Blood and Blood Forming Organs
  • Cardiovascular Agents
  • Chemical Actions and Uses
  • Chemically-Induced Disorders
  • Cytochrome P-450 CYP1A2 Inhibitors
CAS number55142-85-3

Drug Targets

NameSequence SearchPharmacological ActionActions
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682